Following the COVID-19 pandemic, African countries and development partners have prioritised investment into vaccines manufacturing capacity with a view to overcome health inequities. The Partnership for African Vaccine Manufacturing (PAVM), under Africa CDC was launched in 2021 and its Framework for Action in 2022. PAVM targets a call by the African Union heads of State and Government for the local production of 60% of the vaccine the region requires by 2040.
Around 30 investment initiatives for vaccines manufacturing in Africa have been announced since COVID-19. The key question that the event is intended to address is how to develop sustainable investment in vaccine manufacturing that will mitigate the risks and ensure financial sustainability. For this purpose, the event will:
- Outline the progress made on investment in vaccine manufacturing in Africa, while creating transparency on the current financing gap, as well as the pain points experienced by investment projects to date.
- Provide a platform to facilitate business to business linkages and matchmaking between investors, manufacturers, and financial providers.
- Identify potential solutions to enhance sustainability of investment.
The event will also facilitate initial exchange on the opportunities for investment in biopharmaceuticals that are critical to making vaccines investment sustainable.
There is some issue in accessing document path, Please contact to Site Admin